Peer-reviewed article
Augmentation in depression: Esketamine, a new standard?
Abstract
While new add-on treatments have been developed for augmentation in depression with benefits demonstrated compared to placebo, none have demonstrated superiority compared to previously available interventions until now. In a phase IIIb, randomized, active-controlled trial (ESCAPE-TRD), Reif et al.<sup>1</sup> demonstrate the superiority of esketamine compared to quetiapine augmentation (the current standard-of-care).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleKetamine
Pharmacologic Approaches to Suicide Prevention.
ArticleKetamine
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.
ArticleKetamine